We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Antigen Microarray Aids Diagnosis of Autoimmune Diseases

By Biotechdaily staff writers
Posted on 22 May 2002
A new diagnostic system for autoimmune diseases is based on an antigen microarray, which consists of glass slides dotted with thousands of proteins and other molecules that are often attacked in autoimmune diseases. More...
The microarray system, which is the result of research conducted at the Stanford University Medical Center (Stanford, CA, USA), is described in the March 2002 issue of Nature Medicine.

The antigen microarray assay allows the laboratory to screen a patient's sample for hundreds of antibodies simultaneously. "Right now clinicians test each antigen separately, and each one can take weeks,” said P.J. Utz, M.D., senior author of the study. These arrays could enable a clinician to diagnose the disease on the first visit.”

To use the microarray, doctors draw a blood sample from the patient and incubate it on the array. Those antibodies that recognize molecules on the array will attach and remain bound to them. Fluorescent molecules are added to detect the antibodies, creating colored spots on the slide. A computer then counts the spots to see which antigens the immune system recognized.

Most healthy people do not have antibodies that recognize most of antigens on the array. Diabetics, however, may produce arrays with spots corresponding to pancreas cell proteins, and people with rheumatoid arthritis produce spots that correspond to molecules found in the joints. Microarrays will also help determine who is at future risk of developing a disease because autoantibodies may be formed years before signs of illness appear.

"Even if the patients don't have the disease now, such microarrays may be able to predict which patients are most likely to develop the disease in the next five years,” says William Robinson, lead author of the study. "In the future, it may become possible to identify individuals at higher risk, such as those with a family history of autoimmune disease, so they can begin preventive therapy.”




Related Links:
Stanford University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.